This center primarily treats substance use disorders, helping you stabilize, create relapse-prevention plans, and connect to compassionate support.
Offering intensive care with 24/7 monitoring, residential treatment is typically 30 days and can cover multiple levels of care. Length can range from 14 to 90 days typically.
This provider hasn't verified their profile's information. Are you the owner of this center? Claim your listing to better manage your presence on Recovery.com.
This center primarily treats substance use disorders, helping you stabilize, create relapse-prevention plans, and connect to compassionate support.
Offering intensive care with 24/7 monitoring, residential treatment is typically 30 days and can cover multiple levels of care. Length can range from 14 to 90 days typically.
ClearVision is now in-network with most insurance providers available in 34 Pennsylvania counties. We also work with most PPO insurance's out-of-network benefits.
ClearVision Health and Wellness is a facility that specializes in treating adults with substance use disorders. They offer a medically-assisted detox program where individuals will first receive a medical evaluation and then receive personalized care with 24/7 nursing support. Detox typically takes 7-10 days and ClearVision will work with individuals to manage withdrawal symptoms during this time. They offer detox for alcohol, benzodiazepines, cocaine, heroin, meth, opiates, and prescription pills.
ClearVision also offers a residential treatment program that uses the 12-Step Program. During the program, residents will participate in intensive group and individual therapies, meditation, and yoga. The program will focus on imparting life skills and relapse prevention skills. In addition, residents can expect to receive 5-8 hours of individual counseling a week, to participate in 12-Step and SMART recovery meetings, and to learn about nutrition wellness. The program will typically last 28-90 days for most residents.
ClearVision offers aftercare services and a family program. A certified recovery specialist will work with residents and their counselors to create an individualized aftercare program. Residents will be able to access outpatient care and continued care through ClearVision's partners. ClearVision offers family therapy and encourages family members to participate in their loved one's recovery journey.
This center primarily treats substance use disorders, helping you stabilize, create relapse-prevention plans, and connect to compassionate support.
Medication-Assisted Treatment (MAT) is an evidence-based approach that pairs FDA-approved medications with counseling to treat addiction. The medications are used to reduce cravings, ease withdrawal symptoms, or block the effects of substances. More about MAT
Dolophine®, Methadose®
Methadone is a full opioid agonist, meaning it activates opioid receptors in the brain to produce effects like pain relief and euphoria. It is longer acting than many other opioids, making it useful in medication-assisted treatment for opioid use disorder.
It reduces withdrawal symptoms and cravings by occupying opioid receptors without causing intense highs. Because it is a full agonist, it must be used carefully to avoid overdose, but it is highly effective when taken as prescribed within a structured program.
Vivitrol®, Revia®
Naltrexone is an opioid antagonist, meaning it blocks opioid receptors in the brain and prevents opioids from producing effects like euphoria or sedation. It is used to treat both opioid and alcohol use disorders, but does not cause physical dependence or withdrawal.
It helps reduce cravings and the rewarding effects of opioids or alcohol, supporting long-term recovery. Because it blocks opioid effects, it should only be started after a person has fully detoxed from opioids to avoid triggering withdrawal.
Suboxone®, Subutex®, Sublocade®, Zubsolv®
Buprenorphine is a partial opioid agonist used to treat opioid use disorder. It activates opioid receptors to reduce cravings and withdrawal but has a ceiling effect, meaning it produces less euphoria and respiratory depression than full opioids.
Buprenorphine binds tightly to opioid receptors, blocking other opioids from attaching and reducing the risk of misuse. It's often combined with naloxone (as in Suboxone®) to discourage injection misuse and is available in daily or monthly forms.